SCHEMBL1837639

SCHEMBL1837639

Nc1nccc(-c2c[nH]c3nccc(N4CCN(c5ccccc5)CC4)c23)n1

nearest known ligand 0.60

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 12/20 0.60
CDC42BPB Q9Y5S2 12/20 0.60
ROCK2 O75116 11/20 0.60
CCNT1 O60563 7/20 0.55
CDK9 P50750 7/20 0.55
CDK5 Q00535 7/20 0.55
CDK5R1 Q15078 7/20 0.55
CCNA2 P20248 6/20 0.55
CDK2 P24941 6/20 0.55
CCNA1 P78396 6/20 0.55
PDPK1 O15530 1/20 0.50
CDC42BPA Q5VT25 2/20 0.48
DHFR P00374 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2236999 0.87 ROCK1 (0.73) ROCK1CDC42BPBROCK2CCNT1CDK9
SCHEMBL1834620 0.86 ROCK1 (0.59) ROCK1CDC42BPBROCK2CCNT1CDK9
SCHEMBL1838096 0.86 ROCK1 (0.59) ROCK1CDC42BPBROCK2CCNT1CDK9
SCHEMBL1842497 0.86 ROCK1 (0.75) ROCK1CDC42BPBROCK2CCNT1CDK9
SCHEMBL1839716 0.86 ROCK1 (0.75) ROCK1CDC42BPBROCK2CCNT1CDK9
SCHEMBL27835146 0.85 ROCK1 (0.55) ROCK1CDC42BPBROCK2CCNT1CDK9
SCHEMBL1839627 0.84 CDK5 (0.57) ROCK1CDC42BPBROCK2CCNT1CDK9
SCHEMBL2238251 0.83 CCNT1 (0.57) ROCK1CDC42BPBROCK2CCNT1CDK9
SCHEMBL1838832 0.83 CCNT1 (0.56) ROCK1CDC42BPBROCK2CCNT1CDK9
SCHEMBL1835851 0.83 ROCK1 (0.58) ROCK1CDC42BPBROCK2CCNT1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011526931-A 2011-10-20 JP claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US claimed
CN-102143746-A CDK modulators EXELIXIS INC 2011-08-03 CN claimed
EP-2320895-A2 CDK MODULATORS Exelixis, Inc. (US) 2011-05-18 EP claimed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 WO claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
CN-102143746-A CDK modulators EXELIXIS INC 2011-08-03 CN disclosed
EP-2320895-A2 CDK MODULATORS Exelixis, Inc. (US) 2011-05-18 EP disclosed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 WO disclosed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201599-A1 CDK Modulators CDK3, CDK1, CDKL1 ROCK1 759/4885CDC42BPB 630/4885ROCK2 1231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.